Please login to the form below
Eyeforpharma Real World Evidence Conference Round up 2018
Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)
This year has seen a turning point for Japan's pharma industry, as the government and the industry encourage a rapid move towards increased use of RWE from April 2018. Real World Data (RWD) sources provide an unprecedented opportunity for companies to find, demonstrate and communicate their real value to patients, healthcare and society. The conference included topics addressing commercial and medical needs, allowing both communities to come together for the first time encouraging collaboration across functions...Read the full article: https://www.researchpartnership.com/news/2018/05/eyeforpharma-real-world-evidence-conference-round-u...
Company Details
Research Partnership
+44 (0)20 8069 5000
Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom
Latest content on this profile
- Healthcare in the age of AI: How will artificial intelligence impact future decision-making?
- Authored by: Constanza Salas, Jhon Galindo and Rachel Howard
Research Partnership
- Therapy Watch launches new tracker covering Postpartum Depression
- The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry
Research Partnership
- Value-based pricing reform: Strengthening the ‘front door’ to the Colombian pharmaceutical market
- Authored by: Marc Garcia and Tania Rodrigues
Research Partnership
- Infographic: Rare Diseases in China
- How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.
Research Partnership
- New syndicated COPD report now available
- Living with COPD 2023
Research Partnership
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.
Research Partnership
